LLY vs NVO
Eli Lilly and Company vs Novo Nordisk A/S · Updated Aug 3, 2026
LLY — 11 winsNVO — 10 wins
Price Performance
LLY +45.26%NVO -3.95%
Performance
| LLY | NVO | |
|---|---|---|
| 1 Month | -3.66% | -3.92% |
| 3 Months | +22.85% | +10.99% |
| 6 Months | +12.11% | -21.02% |
| YTD | +6.84% | -7.90% |
| 1 Year | +51.06% | -6.34% |
| 3 Year | +262.37% | -45.72% |
| 5 Year | +692.38% | +33.20% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | +3.4% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
| NVO | -10.5% | -41.9% | -15.8% | +51.1% | +24.4% | +56.0% | +19.7% | +23.7% | -14.9% | +49.4% | -37.4% | +36.7% |
Valuation
| LLY | NVO | |
|---|---|---|
| P/E Ratio | 40.79 | 11.50 |
| Forward P/E | 24.06 | 1.92 |
| PEG Ratio | 1.77 | 5.68 |
| P/S Ratio | 15.59 | 3.81 |
| P/B Ratio | 36.10 | 6.07 |
| EV/EBITDA | 33.46 | 8.36 |
Financials
| LLY | NVO | |
|---|---|---|
| EPS (TTM) | $28.15 | $23.05 |
| Gross Margin | +78.98% | +80.98% |
| Operating Margin | +46.44% | +41.30% |
| Net Margin | +37.36% | +33.14% |
| ROE | +81.01% | +61.10% |
| ROA | +21.68% | +18.87% |
| Debt/Equity | 1.39 | 0.67 |
Growth
| LLY | NVO | |
|---|---|---|
| Revenue Growth YoY | +55.55% | — |
| Revenue Growth QoQ | +2.63% | — |
| EPS Growth YoY | +169.94% | — |
| EPS Growth QoQ | +11.77% | — |
Technical
| LLY | NVO | |
|---|---|---|
| RSI (14) | 49.02 | 47.53 |
| % From 20-Day SMA | -3.09% | -5.51% |
| % From 50-Day SMA | +0.07% | +0.05% |
| % From 200-Day SMA | +12.05% | -0.18% |
| % From 52-Week High | -8.11% | -26.96% |
| % From 52-Week Low | +84.06% | +33.43% |
Analyst Ratings
LLY
Buy(29 analysts)
Strong SellHoldStrong Buy
Price Target
$1315.42
+14.57% upside
NVO
Hold(2 analysts)
Strong SellHoldStrong Buy
Price Target
$45.00
-3.97% upside
Overview
| LLY | NVO | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $1.13T | $176.82B |
| Shares Outstanding | 941.7M | 4.44B |
| Avg Volume (10D) | 2.22M | 10.27M |
| Dividend Yield | 0.54% | 3.09% |
Frequently Asked Questions
Is LLY or NVO a better buy right now?
Based on 21 comparable metrics, LLY leads in 11 categories while NVO leads in 10. LLY has a consensus analyst rating with 29 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, LLY or NVO?
Over the past year, LLY returned +51.06% compared to NVO's -6.34%. In the short term (1 month), LLY returned -3.66% vs NVO's -3.92%.
Is LLY or NVO more expensive?
LLY trades at a P/E of 40.79 compared to NVO's 11.50. On a price-to-sales basis, LLY trades at 15.59x vs NVO's 3.81x. Forward P/E: LLY at 24.06 vs NVO at 1.92.
Which stock has higher growth, LLY or NVO?
LLY's revenue grew +55.55% year-over-year compared to NVO's —. EPS growth: LLY at +169.94% vs NVO at —.
Do LLY and NVO pay dividends?
LLY pays a dividend with a yield of 0.54%. NVO pays a dividend with a yield of 3.09%.
Which stock do analysts prefer, LLY or NVO?
LLY has 29 analysts with a target price of $1315.42 (+14.57% upside). NVO has 2 analysts with a target of $45.00 (-3.97% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.